Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

NCT02067156 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma Multiforme

Interventions

DRUG: G-202

Sponsor

GenSpera, Inc.

Collaborators

[object Object]